Cargando…
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria
Background: Emapticap pegol (NOX-E36) is a Spiegelmer(®) that specifically binds and inhibits the pro-inflammatory chemokine C-C motif-ligand 2 (CCL2) (also called monocyte-chemotactic protein 1). The objective of this exploratory study was to evaluate the safety and tolerability as well as the reno...
Autores principales: | Menne, Jan, Eulberg, Dirk, Beyer, Diana, Baumann, Matthias, Saudek, Frantisek, Valkusz, Zsuzsanna, Więcek, Andrzej, Haller, Hermann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410979/ https://www.ncbi.nlm.nih.gov/pubmed/28186566 http://dx.doi.org/10.1093/ndt/gfv459 |
Ejemplares similares
-
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
por: Steurer, Michael, et al.
Publicado: (2019) -
Serum Cystatin C Reflects the Progress of Albuminuria
por: Yoo, Jeong Seon, et al.
Publicado: (2011) -
HLA‐C*06:02 allele can influence clinical efficacy of certolizumab pegol?
por: Dattola, Annunziata, et al.
Publicado: (2021) -
Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021) -
Cystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes
por: de Boer, Ian H., et al.
Publicado: (2009)